Entrada Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Entrada Therapeutics Stock-Based Compensation Growth & History (TRDA)
Entrada Therapeutics's stock-based compensation was $19.6M for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.6M | $1.7M | +9.46% |
| 2024 | 2024-12-31 | $17.9M | $4.8M | +36.64% |
| 2023 | 2023-12-31 | $13.1M | $3.2M | +32.50% |
| 2022 | 2022-12-31 | $9.9M | $7.4M | +291.73% |
| 2021 | 2021-12-31 | $2.5M | $2.2M | +677.23% |
| 2020 | 2020-12-31 | $325,000 | — | — |
Entrada Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.2M | $102,000 | +2.02% |
| Q1 2026 | 2026-03-31 | $4.7M | −$343,000 | −6.74% |
| Q4 2025 | 2025-12-31 | $4.4M | −$342,000 | −7.28% |
| Q3 2025 | 2025-09-30 | $5.1M | $256,000 | +5.27% |
| Q2 2025 | 2025-06-30 | $5.0M | $426,000 | +9.22% |
| Q1 2025 | 2025-03-31 | $5.1M | $1.4M | +36.27% |
| Q4 2024 | 2024-12-31 | $4.7M | $859,000 | +22.36% |
| Q3 2024 | 2024-09-30 | $4.9M | $1.5M | +43.11% |
| Q2 2024 | 2024-06-30 | $4.6M | $1.5M | +48.19% |
| Q1 2024 | 2024-03-31 | $3.7M | $978,000 | +35.50% |
| Q4 2023 | 2023-12-31 | $3.8M | $959,000 | +33.28% |
| Q3 2023 | 2023-09-30 | $3.4M | $689,000 | +25.45% |
| Q2 2023 | 2023-06-30 | $3.1M | $607,000 | +24.16% |
| Q1 2023 | 2023-03-31 | $2.8M | $961,000 | +53.57% |
| Q4 2022 | 2022-12-31 | $2.9M | $1.4M | +97.67% |
| Q3 2022 | 2022-09-30 | $2.7M | $2.1M | +368.34% |
| Q2 2022 | 2022-06-30 | $2.5M | $2.2M | +670.55% |
| Q1 2022 | 2022-03-31 | $1.8M | $1.6M | +993.90% |
| Q4 2021 | 2021-12-31 | $1.5M | — | — |
| Q3 2021 | 2021-09-30 | $578,000 | $503,000 | +670.67% |
| Q2 2021 | 2021-06-30 | $326,000 | — | — |
| Q1 2021 | 2021-03-31 | $164,000 | — | — |
| Q3 2020 | 2020-09-30 | $75,000 | — | — |
Entrada Therapeutics stock-based compensation trends
Over the last five fiscal years, Entrada Therapeutics's stock-based compensation increased from $325,000 to $19.6M, a change of $19.3M. The latest reported quarter, Q2 2026, shows $5.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗